TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15848672

Group type: COMPARATOR
Intervention: Prograf twice a day (days 14 and 42)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (days 28 and 56)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prograf twice a day (day 14)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (day 28)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Prograf twice a day (day 42)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: MR tacrolimus once daily (day 56)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 70
Study: 11973248

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for up to 6 weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment for 4 or more weeks
Number of subjects: 11
Study: 8201751

Group type: EXPERIMENTAL
Intervention: pH sensor feeding tube
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard feeding tube
Number of subjects: 39
Study: 3297575

Group type: EXPERIMENTAL
Intervention: Education group
Number of subjects: 345

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study: 30717690

Group type: EXPERIMENTAL
Intervention: Intravenous Ferric Carboxymaltose (FCM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous Iron sucrose complex (ISC)
Number of subjects: 100
Study: 28527704

Group type: EXPERIMENTAL
Intervention: PF-00547659 7.5 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: PF-00547659 22.5 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: PF-00547659 75 mg
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: PF-00547659 225 mg
Number of subjects: 357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study: 25746580

Group type: EXPERIMENTAL
Intervention: α‐adrenergic agonist (midodrine) plus an anticholinergic (solifenacin)
Number of subjects: 78

Group type: COMPARATOR
Intervention: α‐adrenergic agonist only
Number of subjects: 78
Study: 22931254

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Thoracolumbar X-ray
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA) and Thoracolumbar X-ray
Number of subjects: 1983
Study: 20950801

Group type: EXPERIMENTAL
Intervention: Dynamic position changes during colonoscope withdrawal
Number of subjects: 130
Study: 19463883

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16974184

Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ) 10-20 mg/d
Number of subjects: 346

Group type: COMPARATOR
Intervention: Quetiapine (QUE) 300-700 mg/d
Number of subjects: 346
Study: 15223883

Group type: EXPERIMENTAL
Intervention: 8-week strength and flexibility program
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 11279409

Group type: EXPERIMENTAL
Intervention: Off-pump treatment on the beating heart
Number of subjects: 200

Group type: COMPARATOR
Intervention: On-pump treatment with conventional cardiopulmonary bypass
Number of subjects: 200
Study: 9253309

Group type: EXPERIMENTAL
Intervention: Carbimazole by a titration regimen (Group A, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Higher doses of carbimazole plus T4 (Group B, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 60
Study: 8463869

Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with 20 g of unabsorbed sugar lactulose
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Polysaccharide-free diet with 20 g of fermentable fiber, guar
Number of subjects: 12

Group type: COMPARATOR
Intervention: Polysaccharide-free diet alone
Number of subjects: 12
Study: 2834257

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg every 6 h s.c.)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg every 6 h s.c.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (saline 1 ml every 6 h s.c.)
Number of subjects: 12
Study: 30461007

Group type: EXPERIMENTAL
Intervention: 48-h mortality risk score based on age, sex, haemoglobin level, serum creatinine level, systolic BP, aortic neck length and angle, and acute myocardial ischaemia.
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: 48-h mortality risk score
Number of subjects: 536
Study: 28158200

Group type: EXPERIMENTAL
Intervention: Online tool (Intervention condition, IC)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Active control tool (CC)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Online tool (IC)
Number of subjects: 408
Study: 25171663

Group type: EXPERIMENTAL
Intervention: Low dose triamcinolone hexacetonide (20 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High dose triamcinolone hexacetonide (40 mg)
Number of subjects: 60
Study: 23279923

Group type: EXPERIMENTAL
Intervention: Lanca perfume use
Number of subjects: 0
Study: 21191857

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study: 19644905

Group type: EXPERIMENTAL
Intervention: Naturopathic care (NC)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standardized physical exercises (PE)
Number of subjects: 85
Study: 17654051

Group type: EXPERIMENTAL
Intervention: Polyphenol-rich food (PRF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Polyphenol-free food (PFF)
Number of subjects: 21
Study: 15089941

Group type: EXPERIMENTAL
Intervention: Protect Liner F
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Health-Dent Desensitizer
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fluoline varnish
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Single Bond
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer
Number of subjects: 52
Study: 11318462

Group type: EXPERIMENTAL
Intervention: Trimetazidine, prednisolone and complex B vitamins (Group A)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Trimetazidine (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Prednisolone and complex B vitamins (Group C)
Number of subjects: 72
Study: 9035015

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg bid (E200)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Etodolac 300 mg bid (E300)
Number of subjects: 426

Group type: COMPARATOR
Intervention: Piroxicam 20 mg qd (P20)
Number of subjects: 426
Study: 7706507

Group type: EXPERIMENTAL
Intervention: 65% CO2 + 35% O2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 20
Study: 3667002

Group type: EXPERIMENTAL
Intervention: Aggressive medical and surgical management
Number of subjects: 1
Study: 29566739

Group type: EXPERIMENTAL
Intervention: Training in mental health components of Primary Care 101 (PC101) and clinical communications skills training, supplemented with a clinic-based behavioural health counsellor providing manualised depression counselling (eight sessions, individual or group) and adherence counselling sessions (one session, individual).
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group implementing the South African Department of Health's Integrated Clinical Services Management model, including training in PC101 covering communicable diseases, NCDs, women's health, and mental disorders.
Number of subjects: 2000
Study: 26511262

Group type: EXPERIMENTAL
Intervention: Light-emitting wire pathologic duct marking
Number of subjects: 69

Group type: COMPARATOR
Intervention: Methylene blue pathologic duct marking
Number of subjects: 69
Study: 26386790

Group type: EXPERIMENTAL
Intervention: Higher dose edoxaban
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: Lower dose edoxaban
Number of subjects: 21105

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105

Group type: EXPERIMENTAL
Intervention: NOACs (meta-analysis of 4 warfarin-controlled phase 3 AF trials)
Number of subjects: 21105
Study: 24416747

Group type: EXPERIMENTAL
Intervention: Azelaic acid foam 15%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 21534652

Group type: EXPERIMENTAL
Intervention: Internet-based therapy (TAO)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Internet-based self-help (SAO)
Number of subjects: 205
Study: 18240190

Group type: EXPERIMENTAL
Intervention: Patients with moderately severe to severe symptoms of depression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Patients rated by physicians as having worse ACR functional status
Number of subjects: 200
Study: 16627032

Group type: EXPERIMENTAL
Intervention: Vaginal ring
Number of subjects: 201

Group type: COMPARATOR
Intervention: Low-dose oral contraceptive
Number of subjects: 201
Study: 14564679

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10964188

Group type: EXPERIMENTAL
Intervention: Complementary therapies (specific therapies not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized control trials (RCTs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complementary therapy research methods
Number of subjects: 0
Study: 9006241

Group type: EXPERIMENTAL
Intervention: Psychoeducational group program
Number of subjects: 191
Study: 1620831

Group type: EXPERIMENTAL
Intervention: Injection of 160‐mL dose of Optiray 320 (ioversol) at 3.0 mL/sec (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Injection of 160‐mL dose of Optiray 320 (ioversol) at 4.5 mL/sec (group 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 50
Study: 6736339

Group type: EXPERIMENTAL
Intervention: Oral 8‐methoxypsoralen photochemotherapy (PUVA)
Number of subjects: 10
Study: 31237065

Group type: EXPERIMENTAL
Intervention: Ultramicronized palmitoylethanolamide (PEA-um) 15 mg/kg per os, once daily; n=29
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo; n=28
Number of subjects: 57
Study: 29439942

Group type: EXPERIMENTAL
Intervention: Robot delivering telehealth care for 4 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care control group
Number of subjects: 60
Study: 26718899

Group type: EXPERIMENTAL
Intervention: VAC therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dressings
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: VAC therapy in venous ulcers
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional dressings in venous ulcers
Number of subjects: 46
Study: 25163699

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lexaptepid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22161738

Group type: EXPERIMENTAL
Intervention: Iloperidone 10-16 mg/day
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Iloperidone 20-24 mg/day
Number of subjects: 2401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Iloperidone (all doses)
Number of subjects: 2401

Group type: EXPERIMENTAL
Intervention: Iloperidone (higher doses)
Number of subjects: 2401
Study: 19880504

Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg every 8 h for 3 days)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 17598699

Group type: EXPERIMENTAL
Intervention: Test FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference FDC (Esomeprazole 40 mg and Domperidone 30 mg)
Number of subjects: 24
Study: 15128070

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 11496091

Group type: EXPERIMENTAL
Intervention: New ECG trigger method (group 1)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 80% R‐R interval trigger method (group 2)
Number of subjects: 214
Study: 9728854

Group type: EXPERIMENTAL
Intervention: IV infusion of clonidine (4 microg/kg in 20 min followed by 2 microg x kg(‐1) x h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV infusion of sufentanil (0.2 microg x kg(‐1) x h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: IV infusion of ketamine (0.5 mg/kg followed by 0.25 mg x kg(‐1) x h(‐1))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural infusion of bupivacaine (7 mL of 0.5% followed by 5 mL/h of 0.25%)
Number of subjects: 60
Study: 8034875

Group type: EXPERIMENTAL
Intervention: Biphasic device
Number of subjects: 91

Group type: COMPARATOR
Intervention: Monophasic device
Number of subjects: 91
Study: 2658536

Group type: EXPERIMENTAL
Intervention: Xylitol (30 g in 200 mL water)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose (30 g in 200 mL water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Xylitol (30 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucose (30 g)
Number of subjects: 0
Study: 10944

Group type: EXPERIMENTAL
Intervention: Hydrochloride preparation of oxytetracycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Film-coated tablets of oxytetracycline dihydrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sugar-coated tablets of oxytetracycline dihydrate
Number of subjects: 0
Study: 31610828

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 3
Study: 30329224

Group type: EXPERIMENTAL
Intervention: CKD-395 0.5/1000 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Coadministration of lobeglitazone sulfate 0.5 mg and metformin HCl XR 1000 mg
Number of subjects: 42
Study: 29097660

Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Stress group (Low and High cortisol responders)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 62
Study: 26011583

Group type: EXPERIMENTAL
Intervention: High-frequency EMA (six times daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Low-frequency EMA (once daily)
Number of subjects: 110
Study: 24002488

Group type: EXPERIMENTAL
Intervention: Latrine promotion intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mass azithromycin distribution
Number of subjects: 12
Study: 21959871

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for all HER2-positive populations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for IHC 2+/FISH+ or IHC 3+ population
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy for IHC 3+ population
Number of subjects: 0
Study: 19843557

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP1521) plus AIDSVAX B/E vaccine regimen
Number of subjects: 16402
Study: 16313821

Group type: EXPERIMENTAL
Intervention: Group A (digestive tract reconstruction by manual end-to-side anastomosis of residual stomach and jejunum, end-to-side anastomosis of residual duodenum and jejunum, and side-to-side anastomosis of jejunum and jejunum)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group B (Bilroth digestive tract reconstruction)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 54

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 54
Study: 12142757

Group type: EXPERIMENTAL
Intervention: Intraoperative retrobulbar 95% ethanol injections
Number of subjects: 11

Group type: COMPARATOR
Intervention: Retrobulbar 0.75% bupivacaine with 1:100,000 epinephrine
Number of subjects: 11
Study: 9990383

Group type: EXPERIMENTAL
Intervention: Topical betamethasone‐17‐valerate
Number of subjects: 1
Study: 7532878

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study: 1972599

Group type: EXPERIMENTAL
Intervention: Formoterol 24 micrograms twice daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Salbutamol 400 micrograms twice daily
Number of subjects: 16
Study: 336450

Group type: EXPERIMENTAL
Intervention: Graded doses of lactose (0 to 18 g) in breakfast meals, randomized and double-blinded.
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lactose equivalent to 1 to 1 1/2 glasses of milk taken with a meal.
Number of subjects: 59
Study: 31823902

Group type: EXPERIMENTAL
Intervention: PRP with minoxidil
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: PRP alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Minoxidil alone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 80
Study: 31151360

Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers
Number of subjects: 15
Study: 28653776

Group type: EXPERIMENTAL
Intervention: Telephone call
Number of subjects: 1188

Group type: EXPERIMENTAL
Intervention: SMS
Number of subjects: 1188

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1188
Study: 25568929

Group type: EXPERIMENTAL
Intervention: Baseline 6-minute walk distance (6MWD)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Accelerometry steps
Number of subjects: 326

Group type: COMPARATOR
Intervention: GOLD classification
Number of subjects: 326
Study: 23668668

Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapists and trained raters
Number of subjects: 0
Study: 21326115

Group type: EXPERIMENTAL
Intervention: Perianal pouch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Adult containment brief
Number of subjects: 30
Study: 19335751

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at a dosage of 90 microg kg(‐1) repeated every 3 h if needed
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Activated prothrombin complex concentrate (aPCC) at a dosage of 75 IU kg(‐1) repeated every 12 h if needed
Number of subjects: 2000
Study: 17045492

Group type: EXPERIMENTAL
Intervention: Eigenimage classification model
Number of subjects: 60
Study: 15286957

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 99

Group type: COMPARATOR
Intervention: Open Nissen fundoplication
Number of subjects: 99
Study: 11560814

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9630111

Group type: EXPERIMENTAL
Intervention: Diabetics with LEAD and CAD
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Nondiabetics with LEAD and CAD
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting surgery
Number of subjects: 1400
Study: 7524203

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 101

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 101
Study: 3350031

Group type: COMPARATOR
Intervention: Intervention not specified in the abstract, but involved antihypertensive regimens.
Number of subjects: 551
Study: 29746373

Group type: COMPARATOR
Intervention: ondansetron 4 mg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: droperidol 0.625 mg
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: droperidol 1.25 mg
Number of subjects: 297
Study: 27039383

Group type: EXPERIMENTAL
Intervention: Milk containing both A1 and A2 β‐casein
Number of subjects: 45

Group type: COMPARATOR
Intervention: Milk containing only A2 β‐casein
Number of subjects: 45
Study: 25708282

Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL) with riboflavin (0.1 in 20 % dextran) and UVA radiation (365 nm, 3 mW/cm(2), 30 min)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Collagen cross-linking (CXL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham group (riboflavin only, no UVA)
Number of subjects: 43
Study: 23955482

Group type: EXPERIMENTAL
Intervention: 300 μg Se/day as high‐Se yeast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo yeast
Number of subjects: 16
Study: 19856321

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional rate ratio model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rate difference model
Number of subjects: 0
Study: 17890759

Group type: EXPERIMENTAL
Intervention: Cognitive lifestyle program focusing on weight loss, diet, and exercise; details on dosage and duration not specified.
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care; details on dosage and duration not specified.
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Cognitive lifestyle program; details on dosage and duration not specified.
Number of subjects: 241
Study: 15983303

Group type: EXPERIMENTAL
Intervention: Supplemental computer multimedia use (intervention)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard of care only (control)
Number of subjects: 244
Study: 12473989

Group type: EXPERIMENTAL
Intervention: Long-term protocol (LTP) - 60 micro g PGE1, 5 days each week for 4 weeks, followed by twice a week for 4 weeks, then no treatment for 40 weeks.
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Short-term protocol (STP) - 60 micro g PGE1 twice a day for 2 days, repeated every 4 weeks.
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Cost of LTP protocol
Number of subjects: 1276

Group type: EXPERIMENTAL
Intervention: Cost of STP protocol
Number of subjects: 1276
Study: 10520386

Group type: EXPERIMENTAL
Intervention: Tropisetron 5 mg (group T)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg (group O)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Saline (group C)
Number of subjects: 121
Study: 8643964

Group type: EXPERIMENTAL
Intervention: Paclitaxel (200 mg/m2) and Doxorubicin (60 mg/m2) administered in alternating schedules (3-hour infusion for paclitaxel and intravenous bolus for doxorubicin)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and Doxorubicin (60 mg/m2) administered with a 30-minute doxorubicin infusion preceding a 3-hour paclitaxel infusion every 3 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Higher dose levels of paclitaxel/doxorubicin (175 mg/m2 and 60 mg/m2)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study: 2343728

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Methohexital 2 mg/kg
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Midazolam 0.3 mg/kg
Number of subjects: 87

Group type: COMPARATOR
Intervention: Suxamethonium
Number of subjects: 87
Study: 7390377

Group type: EXPERIMENTAL
Intervention: Bromopride (one capsule three times daily for three weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (one capsule three times daily for three weeks)
Number of subjects: 31
Study: 31910054

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical (MIS) group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Open group
Number of subjects: 171